Locoregional radiotherapy was associated with longer survival in de novo metastatic HNSCC
In de novo metastatic HNSCC, locoregional radiotherapy and first-line immunotherapy were independently associated with longer overall survival.
In de novo metastatic HNSCC, locoregional radiotherapy and first-line immunotherapy were independently associated with longer overall survival.
Reduced ipsilateral mucosal irradiation produced 90% five-year survival in p16-positive unknown-primary disease, with no out-of-field mucosal or neck failures.